Tetraphase Pharmaceuticals is a technology company.
Tetraphase Pharmaceuticals has raised $95.0M across 4 funding rounds.
Tetraphase Pharmaceuticals has raised $95.0M in total across 4 funding rounds.
Tetraphase Pharmaceuticals has raised $95.0M in total across 4 funding rounds.
Tetraphase Pharmaceuticals's investors include Flagship Ventures.
Tetraphase Pharmaceuticals (NASDAQ: TTPH) was a clinical-stage biopharmaceutical company that developed novel antibiotics using proprietary chemistry technology to combat serious and life-threatening multidrug-resistant bacterial infections.[1][2] Its lead product, XERAVA (eravacycline), received FDA and EMA approval for treating complicated intra-abdominal infections, targeting pathogens identified as urgent threats by the WHO and CDC.[1][2] The company served healthcare providers and patients facing limited treatment options for resistant infections but was ultimately acquired by La Jolla Pharmaceutical Company, marking the end of its independent operations.[1]
Founded in 2006, Tetraphase emerged from innovation in tetracycline chemistry to address the growing crisis of antibiotic resistance.[1][2] Backed early by venture firms like F-Prime Capital (initial investment in 2006) and Flagship Pioneering, the company advanced its pipeline from preclinical stages to clinical development, achieving public listing on NASDAQ and regulatory approval for XERAVA as a pivotal milestone.[1][2] These partnerships provided the capital and expertise needed to navigate biopharma challenges, leading to its acquisition.
Tetraphase rode the critical wave of antimicrobial resistance, a global health crisis driving demand for innovative antibiotics amid declining industry investment in this high-risk area.[2] Its timing aligned with rising multidrug-resistant threats noted by the WHO and CDC, filling gaps left by legacy drugs and influencing biopharma's push toward targeted therapies.[1][2] By demonstrating viable paths to approval and acquisition, Tetraphase contributed to the ecosystem, validating chemistry-driven approaches and encouraging follow-on investments in resistant-infection solutions despite financial hurdles like high CapEx and operating losses.[3]
Post-acquisition by La Jolla, Tetraphase's assets, including XERAVA, integrate into a broader portfolio, potentially expanding market reach amid ongoing resistance trends.[1] Evolving dynamics like regulatory incentives for antibiotics and AI-aided drug discovery could sustain momentum for similar platforms, though legacy challenges such as high costs and share dilution highlight risks in biopharma scaling.[3] Its story underscores the high-stakes reward of tackling life-threatening infections, shaping a more resilient antibiotic pipeline for the future.
Tetraphase Pharmaceuticals has raised $95.0M across 4 funding rounds. Most recently, it raised $45.0M Series C in May 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2010 | $45.0M Series C | Flagship Ventures | |
| Sep 1, 2009 | $25.0M Series B | Flagship Ventures | |
| Aug 1, 2008 | $15.0M Series A | Flagship Ventures | |
| Oct 1, 2006 | $10.0M Series A | Flagship Ventures |